Malaria continues to be one of the most crucial infectious burdens in endemic areas worldwide, as well as for travelers visiting malaria transmission regions. It has been reported that 8-aminoquinolines are effective against the Plasmodium species, particularly primaquine, for anti-hypnozoite therapy in P. vivax malaria. However, primaquine causes acute hemolytic anemia in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Therefore, G6PD deficiency testing should precede hypnozoite elimination with 8-aminoquinoline. Several point-of-care devices have been developed to detect G6PD deficiency. The aim of the present study was to evaluate the performance of a novel, quantitative G6PD diagnostics based on a metagenomic blue fluorescent protein (mBFP). We comparatively evaluated the sensitivity and specificity of the G6PD diagnostic modality with standard methods using 120 human whole blood samples. The G6PD deficiency was spectrophotometrically confirmed. The performance of the G6PD quantitative test kit was compared with that of a licensed control medical device, the G6PD strip. The G6PD quantitative test kit had a sensitivity of 95% (95% confidence interval (CI): 89.3-100%) and a specificity of 100% (95% CI: 94.3-100%). This study shows that the novel diagnostic G6PD quantitative test kit could be a cost-effective and time-efficient, and universally mandated screening tool for G6PD deficiency.
Citations
Citations to this article as recorded by
Performance of quantitative point-of-care tests to measure G6PD activity: An individual participant data meta-analysis Arkasha Sadhewa, Ari Winasti Satyagraha, Mohammad Shafiul Alam, Wondimagegn Adissu, Anup Anvikar, Germana Bancone, Praveen K. Bharti, Vinod K. Bhutani, Santasabuj Das, Muzamil Mahdi Abdel Hamid, Mohammad Sharif Hossain, Nitika Nitika, Bernard A. Okech, Ly PLOS Neglected Tropical Diseases.2025; 19(3): e0012864. CrossRef
Utilization of Glucose-6-Phosphate Dehydrogenase Test and the Prevalence of Enzyme Deficiency in Korea Rihwa Choi, Wonseo Park, Gayoung Chun, Sang Gon Lee, Eun Hee Lee Journal of Clinical Medicine.2023; 12(9): 3179. CrossRef
Erythrocytes deficient in glucose-6-phosphate dehydrogenase (G6PD) is more susceptible to oxidative damage from free radical derived compounds. The hemolysis triggered by oxidative agents such as primaquine (PQ) is used for the radical treatment of hypnozoites of P. vivax. Testing of G6PD screening before malaria treatment is not a common practice in Thailand, which poses patients at risk of hemolysis. This retrospective study aimed to investigate the prevalence of G6PD in malaria patients who live in Southern Thailand. Eight hundred eighty-one malaria patients were collected for 8-year from 2012 to 2019, including 785 (89.1%) of P. vivax, 61 (6.9%) of P. falciparum, 27 (3.1%) of P. knowlesi, and 8 (0.9%) of mixed infections. The DiaPlexC genotyping kit (Asian type) and PCR-RFLP were employed to determine the G6PD variants. The result showed that 5 different types of G6PD variants were identified in 26 cases (2.9%); 12/26 (46.2%) had Mahidol (487G>A) and 11/26 (42.3%) had Viangchan (871G>A) variants, while the rest had Kaiping (1388G>A), Union (1360C>T), and Mediterranean (563C>T) variants. G6PD Songklanagarind (196T>A) variant was not found in the study. Our result did not show a significant difference in the malaria parasite densities in patients between G6PD-deficient and G6PD-normal groups. According to our findings, testing G6PD deficiency and monitoring the potential PQ toxicity in patients who receive PQ are highly recommended.
Citations
Citations to this article as recorded by
Prospective observational study to assess the feasibility and safety of appropriate Plasmodium vivax radical cure with tafenoquine or primaquine after quantitative G6PD testing during pilot implementation in Thailand Prayuth Sudathip, Nardlada Khantikul, Aungkana Saejeng, Stephan Duparc, Penny Grewal Daumerie, Caroline Lynch, Elodie Jambert, Saowanee Viboonsanti, Darin Areechokchai, Jerdsuda Kanjanasuwan, Thannika Thong-ard, Panupong Kowsurat, Isabelle Borghini-Fuhrer BMJ Global Health.2025; 10(4): e016720. CrossRef
Glucose-6-phosphate dehydrogenase deficiency induced hemolytic anemia and methemoglobinemia: a case report in a 7 -year-old female patient Adalgisa Fastuca, Antonio Vergori, Giuseppe Robustelli, Chiara Piccolo, Maria Ragazzo, Maddalena Marinoni, Massimo Agosti Italian Journal of Pediatrics.2025;[Epub] CrossRef
Human genetic variations conferring resistance to malaria Xiaokun Zhang, Jie Wu, Yunxing Peng, Lan Luo, Lu Zhang, Xi Huang, Guoying Chen, Yirong Li, Haoan Yi Journal of Translational Medicine.2025;[Epub] CrossRef
Glucose-6-phosphate dehydrogenase variants in Kachin, Myanmar Zin Moon, Ja Moon Aung, Dorene VanBik, Hae Soo Yun, Sanghyun Lee, Sylvatrie-Danne Dinzouna-Boutamba, Zau Ring, Yeonchul Hong, Dong-Il Chung, Youn-Kyoung Goo Parasites, Hosts and Diseases.2025; 63(4): 360. CrossRef
Hematological Indicators of Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency in Malaria-Infected Individuals Donia Zaid Hazem, Esraa Adel Mahmood, Anfal Saleh Mohammed Malaysian Journal of Medicine and Health Sciences.2024; 20(1): 46. CrossRef
Single-Drop Blood Detection of Common G6PD Mutations in Thailand Based on Allele-Specific Recombinase Polymerase Amplification with CRISPR-Cas12a Punchalee Mungkalasut, Pattaraporn Nimsamer, Poonlarp Cheepsunthorn, Sunchai Payungporn, Chalisa Louicharoen Cheepsunthorn ACS Omega.2023; 8(47): 44733. CrossRef
Prevalence of G6PD deficiency and G6PD variants amongst the southern Thai population Manit Nuinoon, Rungnapha Krithong, Suputcha Pramtong, Piyawit Sasuk, Chompunuch Ngeaiad, Sathanan Chaimusik, Jiraporn Kanboonma, Orawan Sarakul PeerJ.2022; 10: e14208. CrossRef
Cytochrome P450 2D6 (CYP2D6) and glucose-6-phosphate dehydrogenase (G6PD) genetic variations in Thai vivax malaria patients: Implications for 8-aminoquinoline radical cure Kamonwan Chamchoy, Sirapapha Sudsumrit, Thanyapit Thita, Srivicha Krudsood, Rapatbhorn Patrapuvich, Usa Boonyuen, Paul O. Mireji PLOS Neglected Tropical Diseases.2022; 16(12): e0010986. CrossRef
Plasmodium vivax: the potential obstacles it presents to malaria elimination and eradication Kassahun Habtamu, Beyene Petros, Guiyun Yan Tropical Diseases, Travel Medicine and Vaccines.2022;[Epub] CrossRef
Young Yil Bahk, Seong Kyu Ahn, Jinyoung Lee, Jae Hyoung Im, Joon-Sup Yeom, Sookkyung Park, Jeongran Kwon, Hyesu Kan, Miyoung Kim, Woori Jang, Tong-Soo Kim
Korean J Parasitol 2021;59(5):447-455. Published online October 22, 2021
Vivax malaria incidence in Korea is now decreased and showing a low plateau. Nowadays, vivax malaria in Korea is expected to be successfully eliminated with anti-malaria chemotherapy, primaquine, and vector control. The glucose-6-phosphate dehydrogenase (G6PD) deficiency is associated with potential hemolytic anemia after primaquine administration. This inborn disorder has a pivotal polymorphism with genetic variants and is the most prevalent X-chromosome-linked disorder. The prevalence of G6PD deficiency was previously reported negligible in Korea. As the population of multicultural families pertaining marriage immigrants and their adolescents increases, it is necessary to check G6PD deficiency for them prior to primaquine treatment for vivax malaria. The prevalence of G6PD variants and G6PD deficiency in multicultural families was performed in 7 counties and 2 cities of Jeollanam-do (Province), Gyeonggi-do, and Gangwon-do. A total of 733 blood samples of multicultural family participants were subjected to test the phenotypic and genetic G6PD deficiency status using G6PD enzyme activity quantitation kit and PCR-based G6PD genotyping kit. The G6PD phenotypic deficiency was observed in 7.8% of male adolescent participants and 3.2% of materfamilias population. Based on the PCR-based genotyping, we observed total 35 participants carrying the mutated alleles. It is proposed that primaquine prescription should seriously be considered prior to malaria treatment.
Citations
Citations to this article as recorded by
Glucose-6-phosphate dehydrogenase variants in Kachin, Myanmar Zin Moon, Ja Moon Aung, Dorene VanBik, Hae Soo Yun, Sanghyun Lee, Sylvatrie-Danne Dinzouna-Boutamba, Zau Ring, Yeonchul Hong, Dong-Il Chung, Youn-Kyoung Goo Parasites, Hosts and Diseases.2025; 63(4): 360. CrossRef
Georacial Epidemiological Estimates of Glucose-6-Phosphate Dehydrogenase Deficiency among Newborns in the United States Ramesh Vidavalur, Vinod K. Bhutani American Journal of Perinatology.2024; 41(S 01): e1841. CrossRef
Suboptimal Doses of Antimalarials Relative to Increasing Body Weight and the Risk of Plasmodium vivax Recurrence in the Republic of Korea Armed Forces, 2012–2021 Young Hoon Hwang, Doran Yoon, Suryeong Go, Joon-Sup Yeom, Hong Sang Oh Journal of Korean Medical Science.2024;[Epub] CrossRef
Utilization of Glucose-6-Phosphate Dehydrogenase Test and the Prevalence of Enzyme Deficiency in Korea Rihwa Choi, Wonseo Park, Gayoung Chun, Sang Gon Lee, Eun Hee Lee Journal of Clinical Medicine.2023; 12(9): 3179. CrossRef
An Evaluation of a New Quantitative Point-of Care Diagnostic to Measure Glucose-6-phosphate Dehydrogenase Activity Young Yil Bahk, Seong Kyu Ahn, Heung Jin Jeon, Byoung-Kuk Na, Sung-Keun Lee, Ho-Joon Shin The Korean Journal of Parasitology.2022; 60(4): 281. CrossRef
First
Prev
